Literature DB >> 16314839

Loss of interleukin-2-dependency in HTLV-I-infected T cells on gene silencing of thioredoxin-binding protein-2.

M K Ahsan1, H Masutani, Y Yamaguchi, Y-C Kim, K Nosaka, M Matsuoka, Y Nishinaka, M Maeda, J Yodoi.   

Abstract

The transition from interleukin-2 (IL-2)-dependent to IL-2-independent growth is considered one of the key steps in the transformation of human T-cell leukemia virus type-I (HTLV-I)-infected T cells. The expression of thioredoxin-binding protein-2 (TBP-2) is lost during the transition of HTLV-I-infected T-cell lines. Here, we analysed the mechanism of loss of TBP-2 expression and the role of TBP-2 in IL-2-dependent growth in the in vitro model to investigate multistep transformation of HTLV-I. CpGs in the TBP-2 gene are methylated in IL-2-independent but not in IL-2-dependent cells. Sequential treatment with 5-aza-2'-deoxycytidine and a histone deacetylase inhibitor augmented histone acetylation and TBP-2 expression, suggesting that loss of TBP-2 expression is due to DNA methylation and histone deacetylation. In IL-2-dependent cells, a basal level of TBP-2 expression was maintained by IL-2 associated with cellular growth, whereas TBP-2 expression was upregulated on deprivation of IL-2 associated with growth suppression. Overexpression of TBP-2 in IL-2-independent cells suppressed the growth and partially restored responsiveness to IL-2. Knockdown of TBP-2 caused the IL-2-dependent cells to show partial growth without IL-2. These results suggested that epigenetic silencing of the TBP-2 gene results in a loss of responsiveness to IL-2, contributing to uncontrolled IL-2-independent growth in HTLV-I-infected T-cell lines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16314839     DOI: 10.1038/sj.onc.1209256

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities.

Authors:  Zhi Huang; Aaron H Rose; Peter R Hoffmann
Journal:  Antioxid Redox Signal       Date:  2012-01-09       Impact factor: 8.401

Review 2.  HTLV-1 p13, a small protein with a busy agenda.

Authors:  Micol Silic-Benussi; Roberta Biasiotto; Vibeke Andresen; Genoveffa Franchini; Donna M D'Agostino; Vincenzo Ciminale
Journal:  Mol Aspects Med       Date:  2010-03-21

3.  Thioredoxin Interacting Protein (TXNIP) and Pathogenesis of Diabetic Retinopathy.

Authors:  Lalit P Singh
Journal:  J Clin Exp Ophthalmol       Date:  2013-08-05

4.  Molecular characterization of differentially expressed TXNIP gene and its association with porcine carcass traits.

Authors:  Min Liu; Xianfeng Ling; Yuanzhu Xiong; Dequan Xu
Journal:  Mol Biol Rep       Date:  2012-10-09       Impact factor: 2.316

Review 5.  Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.

Authors:  Samuel Lee; Soo Min Kim; Richard T Lee
Journal:  Antioxid Redox Signal       Date:  2012-06-26       Impact factor: 8.401

Review 6.  Selenium and asthma.

Authors:  Robert L Norton; Peter R Hoffmann
Journal:  Mol Aspects Med       Date:  2011-10-15

7.  Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation.

Authors:  Z Chen; D A Lopez-Ramos; E Yoshihara; Y Maeda; H Masutani; K Sugie; M Maeda; J Yodoi
Journal:  Leukemia       Date:  2010-12-10       Impact factor: 11.528

8.  Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus.

Authors:  Hiroshi Masutani; Eiji Yoshihara; So Masaki; Zhe Chen; Junji Yodoi
Journal:  J Clin Biochem Nutr       Date:  2011-10-26       Impact factor: 3.114

9.  Molecular hallmarks of adult T cell leukemia.

Authors:  Makoto Yamagishi; Toshiki Watanabe
Journal:  Front Microbiol       Date:  2012-09-17       Impact factor: 5.640

10.  Development of a novel cell-based assay system EPISSAY for screening epigenetic drugs and liposome formulated decitabine.

Authors:  Sue Ping Lim; Raman Kumar; Yamini Akkamsetty; Wen Wang; Kristen Ho; Paul M Neilsen; Diego J Walther; Rachel J Suetani; Clive Prestidge; David F Callen
Journal:  BMC Cancer       Date:  2013-03-13       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.